Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $66.69 Consensus PT from Brokerages
Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) have been given an average rating of “Buy” by the thirteen analysts that are presently covering the firm, MarketBeat.com reports. Thirteen research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on […]
Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) have been given an average rating of “Buy” by the thirteen analysts that are presently covering the firm, MarketBeat.com reports. Thirteen research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on […]
